Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 16
2021
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$700,000
$14.0 P/Share
|
|
Apr 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.88%
|
$21,000
$42.82 P/Share
|
|
Apr 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.05%
|
$25,800
$43.41 P/Share
|
|
Mar 25
2021
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.82%
|
$3,362
$41.16 P/Share
|
|
Mar 22
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
978
+1.0%
|
$3,912
$4.31 P/Share
|
|
Mar 15
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.86%
|
$23,000
$46.77 P/Share
|
|
Mar 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$115,000
$46.77 P/Share
|
|
Mar 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Mar 10
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.72%
|
$312,500
$50.74 P/Share
|
|
Mar 10
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
Mar 05
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-7.96%
|
$240,000
$48.62 P/Share
|
|
Mar 05
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.37%
|
$15,000
$3.2 P/Share
|
|
Mar 01
2021
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+11.08%
|
-
|
|
Mar 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.03%
|
$28,800
$48.58 P/Share
|
|
Mar 01
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
2,000
-46.01%
|
$100,000
$50.0 P/Share
|
|
Mar 01
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+31.51%
|
$6,000
$3.76 P/Share
|
|
Mar 01
2021
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+14.35%
|
-
|
|
Feb 16
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$115,000
$46.0 P/Share
|
|
Feb 16
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Feb 16
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.85%
|
$23,000
$46.0 P/Share
|
|
Feb 10
2021
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-0.49%
|
$21,996
$47.72 P/Share
|
|
Feb 10
2021
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,523
-0.21%
|
$118,581
$47.72 P/Share
|
|
Feb 10
2021
|
Federico Grossi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-1.15%
|
$32,336
$47.72 P/Share
|
|
Feb 10
2021
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-1.61%
|
$6,768
$47.72 P/Share
|
|
Feb 10
2021
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-3.52%
|
$32,336
$47.72 P/Share
|
|
Feb 10
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-0.08%
|
$32,336
$47.72 P/Share
|
|
Feb 10
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
153
-6.12%
|
$7,191
$47.72 P/Share
|
|
Feb 10
2021
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
858
-2.44%
|
$40,326
$47.72 P/Share
|
|
Feb 10
2021
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
680
-2.27%
|
$31,960
$47.72 P/Share
|
|
Feb 09
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
2,000
-44.44%
|
$100,000
$50.0 P/Share
|
|
Feb 09
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+30.77%
|
$6,000
$3.76 P/Share
|
|
Feb 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.0%
|
$26,400
$44.0 P/Share
|
|
Jan 28
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+0.54%
|
-
|
|
Jan 28
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jan 28
2021
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+35.9%
|
-
|
|
Jan 28
2021
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+44.6%
|
-
|
|
Jan 28
2021
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+33.33%
|
-
|
|
Jan 28
2021
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+33.33%
|
-
|
|
Jan 28
2021
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+13.48%
|
-
|
|
Jan 28
2021
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+4.64%
|
-
|
|
Jan 28
2021
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+14.47%
|
-
|
|
Jan 28
2021
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+1.52%
|
-
|
|
Jan 28
2021
|
Federico Grossi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+7.21%
|
-
|
|
Jan 28
2021
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+19.27%
|
-
|
|
Jan 27
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
43,483
+22.35%
|
$173,932
$4.04 P/Share
|
|
Jan 27
2021
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,777
+2.98%
|
$287,108
$4.04 P/Share
|
|
Jan 25
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+13.31%
|
$45,000
$3.48 P/Share
|
|
Jan 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$132,500
$53.15 P/Share
|
|
Jan 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Jan 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-10.04%
|
$204,000
$51.99 P/Share
|